Warnex Reports First Quarter 2012 Results
(firmenpresse) - LAVAL, QUEBEC -- (Marketwire) -- 05/15/12 -- Warnex Inc. (TSX VENTURE: WNX) ("Warnex") announced today financial results for the first quarter ended March 31, 2012.
Operating Highlights
Financial Results
Consolidated revenue for the three-month period ended March 31, 2012, amounted to $3.7 million compared to $5.8 million for the same period last year. Most of the decrease is explained by the sale of the Medical Laboratories division, on December 8, 2001, which generated $1.4 million in revenues for Q1 of 2011 and nil for 2012.
Net loss for the quarter amounted to $863,945 or $0.01 per share compared to net loss of $67,814 or $0.00 per share for the same quarter in 2011.
General and administrative expenses for the quarter amounted to $1.1 million compared to $1.3 million for the same period last year following the sale of the Medical Laboratories division, on December 8, 2011.
Financial expenses for the quarter remained similar to last year at $0.3 million.
About Warnex
Warnex () is a life sciences company which, through its Bioanalytical Services operations, provides bioequivalence and bioavailability studies for clinical trials at its facility located in Laval, Quebec.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
Certain statements contained in this news release are forward-looking and are subject to numerous risks and uncertainties, known and unknown. For further information identifying known risks and uncertainties, relating to financial resources, liquidity risk, key customers and business partners, credit risk, foreign currency risk, government regulations, laboratory facilities, volatility of share price, employees, suppliers, and other important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the heading Risks and Uncertainties in Warnex's most recent Management's Discussion and Analysis, which can be found at . Consequently, actual results may differ materially from the anticipated results expressed in these forward-looking statements.
Contacts:
Michael Singer
Chairman of the Board of Directors, Warnex Inc.
(514) 940-3610
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 15.05.2012 - 19:56 Uhr
Sprache: Deutsch
News-ID 146887
Anzahl Zeichen: 0
contact information:
Town:
LAVAL, QUEBEC
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 179 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Warnex Reports First Quarter 2012 Results"
steht unter der journalistisch-redaktionellen Verantwortung von
Warnex Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
